摘要
目的:探讨孟鲁司特对幼年哮喘大鼠气道重塑的影响。方法:幼年SD大鼠随机分为模型组、对照组、孟鲁司特组,每组8只。应用卵蛋白致敏、激发8周建立哮喘气道重塑模型,孟鲁司特组每次激发前2 h给予孟鲁司特15 mg/kg灌胃,采用HE染色和计算机图像分析系统测定各组大鼠支气管壁及平滑肌面积,应用样本碱水解法测定羟脯氨酸含量。结果:(1)模型组Wat/Pbm及Wam/Pbm分别为(72.53±5.71)μm和(24.57±2.51)μm,孟鲁司特组Wat/Pbm及Wam/Pbm分别为(63.17±4.99)μm和(16.31±2.14)μm,与模型组比较明显减轻,差异有统计学意义(P<0.05);(2)模型组羟脯氨酸含量为(1 224.51±99.64)μg/g肺组织湿重,高于对照组含量(786.51±78.95)μg/g肺组织湿重,差异有统计学意义(P<0.01);(3)孟鲁司特组羟脯氨酸含量为(1 064.90±86.76)μg/g肺组织湿重,较模型组含量明显减少,差异有统计学意义(P<0.01)。结论:孟鲁司特能显著抑制气道壁平滑肌的增厚、胶原沉积。
Objective： To explore the effect of montelukast in asthmatic airway remodeling in rats. Methods： Twenty four SD rats were randomly divided into three groups： model group, control group and montelukast treatment group. Model group and montelukast treatment group were administrated with Ovalbumin for 8 weeks, however, montelukast treatment group were given montelukast 15 mg/kg through gastric lavage 2 hours before Ovalbumin sensitization. HE staining and image analysis were used to measure Wat/Pbm and Wam/Pbm, and hydroxyproline content were determined in different groups. Results： （ 1 ） The Wat/Pbm and Wam/Pbm, in the model group were （72.53 ±5.71 ） μm and （24.57± 2.51 ） μm, and in montelukast treatment group were （ 63.17 ±4.99 ） μm and （ 16.31 ±2.14）μm. Either in model group or montelukast treatment group, the Wat/Pbm and Wam/Pbm, were obvious increased than those in control group （P〈0.05）. However, the Wat/Pbm and Wam/Pbm in montelukast treatment group were lesser than those in model group （ P〈0.05 ） ; （ 2 ） Hydroxyproline contents of lung tissue in both model and montelukast treatment group were increased than those in control group （P〈0.01）, and in model group were even higher （P〈0.01）. Conclusions： Montelukast can inhibit the airway smooth muscle thickening and collagen deposition.
出处
《儿科药学杂志》
CAS
2012年第3期5-7,共3页
Journal of Pediatric Pharmacy
基金
辽宁省教育厅高等学校科研项目计划(项目编号:20060953)
